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Abstract
Background Tolvaptan, a diuretic with a new mechanism
of action, selectively binds to the vasopressin V2 receptor
and inhibits reabsorption of water. Its effect on heart failure
is proven, but its benefit for patients with chronic kidney
disease (CKD) has not been not confirmed. In this study,
we examined the effect of tolvaptan on patients with severe
CKD.
Methods We analyzed patients with stage 4 or higher
CKD who had congestive heart failure that was resistant to
existing diuretics. The patients were administered an initial
tolvaptan dose of 7.5 mg/day. We assumed urine volume
and urine osmolality to be the main effective endpoint and
recorded free water clearance, serum osmolality, serum
creatinine (Cr) level, and adverse events.
Results There was no instance of clinically significant
hypernatremia. The urine volume increased significantly
(P \ 0.0001), as did the urine osmolality (P = 0.0053).
Free water clearance showed a tendency to increase,
although the difference was not statistically significant. The
serum creatinine level did not change significantly, and
there was no clear effect on renal function. However, in
patients with stage 5 CKD, the serum creatinine level
decreased significantly (n = 5, P = 0.0435). There were
no adverse events.
Conclusion We confirmed that tolvaptan has a diuretic
effect in patients with both severe CKD and congestive
heart failure without causing either clinically significant
hypernatremia or an adverse effect on renal function.
Tolvaptan is an effective diuretic for patients with CKD.
Keywords Tolvaptan  Chronic kidney disease 
Diuretic  Congestive heart failure  Renoprotection
Introduction
Tolvaptan binds selectively to the V2 receptor (1 of the 3
vasopressin receptors: V1a, V1b, and V2), disturbs the
movement of aquaporin 2 into the luminal side of cortical
collecting duct cells through activation of cAMP, and
inhibits reabsorption of water. It thus uses a new mecha-
nism of action for producing water diuresis [1, 2]. The
effect of tolvaptan is expected to be unlike that of con-
ventional diuretics [3], and its short-term effects for treat-
ing heart failure have been investigated in the ACTIVE in
CHF [4] and EVEREST [5, 6] studies. However, careful
administration has been suggested, because volume
depletion by diuresis leads to a decrease in renal blood flow
in patients with serious renal dysfunction; thus, renal
function may worsen [7]. However, one study has sug-
gested that the renal blood flow and glomerular filtration
rate (GFR) are not reduced by tolvaptan [8]. In addition,
the protective function of the kidney is expected to initiate
a diuretic effect without activating the renin–angiotensin
system [9, 10]. There are many unanswered questions
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about the effect of tolvaptan on renal function, and there
are few reports of its use for patients with severe renal
dysfunction [11]. In this report, we examined the effect of
tolvaptan in patients with severe chronic kidney disease
(CKD) complicated by congestive heart failure who were
resistant to existing diuretics.
Subjects and methods
This report is a retrospective observational study of usual
practice, and there was no planned protocol. However, we
explained the likelihood of side effects of tolvaptan, which
was a new medicine, to all patients and obtained their
consent. We included patients with stage 4 CKD or higher
and congestive heart failure who were admitted to our
hospital. The initial tolvaptan dose was 7.5 mg/day. After 2
or 3 days, the dose was increased to 15 mg/day depending
on the observed efficacy and adverse events. The treatment-
targeted value for serum Na concentration controls was set
at 144 mEq/l. If the serum Na concentration increased to
C145 mEq/l, we reduced the tolvaptan dose. Urine volume
and urine osmolality were assumed to be the main effective
endpoint. We evaluated free water clearance, serum
osmolality, serum creatinine (Cr) level, and adverse events.
In addition, we compared values of human atrial natriuretic
peptide (HANP) and B-type natriuretic peptide (BNP)
before the administration of tolvaptan and 1 month later.
The value of each measurement is expressed as
mean ± standard deviation (SD). We conducted one-way
analysis of variance (ANOVA) by considering data mul-
tiplicity over time and used Tukey’s multiple comparison
test for the subsequent post hoc test. We used the paired
t test for comparisons of HANP and BNP values. We
considered P \ 0.05 as statistically significant. In addition,
for each set of data, a regression line was obtained.
Results
Tables 1 and 2 show a summary of the patients’ back-
grounds. The study group consisted of 5 men and 3 women
with a mean age of 53.7 ± 7.7 years and a mean serum Cr
level of 7.57 ± 5.66 mg/dl at admission. Their cardiac
function grade was assessed according to the New York
Heart Association (NYHA) criteria. Five patients were
class II and 3 patients were class III. Primary diseases
included rapidly progressive glomerulonephritis (n = 1),
methicillin-resistant Staphylococcus aureus-associated
nephritis (n = 1), benign nephrosclerosis (n = 1), poly-
cystic kidney disease (n = 3), and diabetic nephropathy
(n = 2). Patients were using the following diuretics: azo-
semide (60 mg/day; n = 1), eplerenone (50 mg/day;
n = 1), torasemide (8 mg/day; n = 2), and furosemide
Table 1 Patient baseline characteristics (N = 8)
Parameter Statistics
Blood pressure (mmHg)
Systolic 155.3 ± 24.8
Diastolic 88.8 ± 17.9
NYHA II:III, n 5:3
HANP (pg/ml) 255.6 ± 236.5
BNP (pg/ml) 1012 ± 1356
sCr (mg/dl) 7.57 ± 5.66
sCr stage 5 (mg/dl) 10.08 ± 5.91
Na (mEq/l) 138.0 ± 6.3
UV (ml/day) 1263 ± 655
uOsm (mOsm/kg) 275.0 ± 39.8
sOsm (mOsm/kg) 296.5 ± 7.6
BNP B-type natriuretic peptide, HANP human atrial natriuretic pep-
tide, NYHA New York Heart Association, uOsm urine osmolality,
sOsm serum osmolality, UV urine volume
Table 2 Patient baseline profile (N = 8)
















1 56 M Nephrosclerosis 5 III 15 180 40
2 64 F PKD 5 II 15 200 40
3 50 M MRSA nephritis 5 III 7.5 120 60 40
4 49 M PKD 5 II 7.5 8 40
5 65 F PKD 5 II 7.5 140 50
6 51 F RPGN 4 II 15 8 40
7 53 M DN 4 II 15 180 40
8 42 M DN 4 III 15 40 40
CKD chronic kidney disease, DN diabetic nephropathy, NYHA New York Heart Association, MRSA nephritis methicillin-resistant Staphylo-
coccus aureus-associated nephritis, PKD polycystic kidney disease
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(40–200 mg/day; n = 6). The renin-angiotensin-aldoster-
one system (RAAS) inhibitor (olmesartan) was prescribed
for 7 patients at a dose of 40 mg. Eplerenone (50 mg) was
prescribed for the remaining 1 patient. No patient took
digitalis.
The dose of tolvaptan remained constant after the 3rd
day, with 5 patients receiving 15 mg/day and 3 receiving
7.5 mg/day. During the course of the study, 1 patient’s Na
concentration exceeded 145 mEq/l; however, this did not
continue for more than 24 h and eventually decreased to
\144 mEq/l. Therefore, we did not reduce the tolvaptan
dose.
Urine volume increased (Fig. 1), with a significant dif-
ference from the next day (P \ 0.0001), and the urine
osmolality decreased similarly (Fig. 2) (P = 0.0010). Free
water clearance showed a tendency to increase, but the







Fig. 4 Changes in serum Na concentration









Fig. 3 Changes in free water clearance






















baFig. 1 Overall changes in 24 h
urine volume (a) and each
change in each patient (b).
*Significant according to the
results of a one-way ANOVA
(P \ 0.0001) and Tukey’s
multiple comparison testing (0
vs. 1, 0 vs. 2, 0 vs. 3, 0 vs. 4, 0





















baFig. 2 Overall changes in urine
osmolality (a) and each change
in each patient (b). *Significant
according to the results of a one-
way ANOVA (P = 0.0010) and
Tukey’s multiple comparison
testing (0 vs. 1, 0 vs. 2, 0 vs. 3, 0
vs. 4, 0 vs. 5)
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difference was not significant (Fig. 3). The serum osmo-
lality showed almost no change, as was the case for the
serum Na concentration (Fig. 4).
The serum Cr level did not show a significant change,
and there was little effect on renal function (Fig. 5a).
However, the serum creatinine level significantly decreased
when it was analyzed for patients with CKD stage 5 alone
(Fig. 5b) (n = 5, P = 0.0435).
HANP and BNP decreased significantly (Fig. 6)
(P = 0.0059 and 0.0055, respectively). However, blood
pressure showed a tendency toward decreasing, but the
difference was not significant (data not shown).
Discussion
In this study, we showed that tolvaptan produced a con-
sistent diuretic effect among patients with severe CKD and
congestive heart failure. If the kidney has some residual
renal function, tolvaptan, which is a water diuretic that
significantly decreases urine osmolality, enables mainte-
nance of the osmoregulation of the body fluids by the renal
cortical collecting tubules. However, clinically significant
hypernatremia did not occur, probably because we used a
natriuretic in combination with tolvaptan. In addition, in
accordance with alleviation of congestion by tolvaptan, the
effect of furosemide may also be improved. This may be
one of the reasons why the urine osmolality and urine
volume did not change in parallel.
A study reported increased renal blood flow after
administration of tolvaptan among patients with heart
failure, but this finding was not observed among patients
with renal failure [8]. The mechanism underlying this
effect is not yet understood. One of the reasons for the
improvement in the serum Cr level in CKD stage 5 patients
may be increased renal blood flow with tolvaptan. Further,
the serum Cr level may have decreased because ‘‘conges-
tive kidney failure’’ [12] was ameliorated by tolvaptan’s
diuretic effect. We acknowledge the likelihood that an
increase in renal blood flow may be caused by the diuretic
effect of tolvaptan in cases in which the effect was not
obtained from diuretics such as furosemide [13]. The effect
and mechanism of action of tolvaptan in the maintenance
of renal function need to be elucidated.
Vasopressin concentrations were not measured in this
study, but it is assumed that they were high [14]. Further,
although our patients were in a state of renal failure, it is



















baFig. 5 Overall changes in
serum Cr level (a) and in stage 5
CKD patients alone (b).
*Significant according to the
results of a one-way ANOVA
(P \ 0.0435) and Tukey’s























P=0.0055baFig. 6 Changes in human atrialnatriuretic peptide (HANP)
(a) and B-type natriuretic
peptide (BNP) (b). P values are
compared with baseline using
the paired t test
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responsive to vasopressin. If this collecting tubule function
was measured and evaluated initially, it would have been
possible to ascertain whether tolvaptan is effective in dis-
orders such as heart failure with advanced renal failure.
In summary, we examined the additive effect of tol-
vaptan among patients using other diuretics for severe
CKD complicated by congestive heart failure. Urine vol-
ume and urine osmolality changed significantly, free water
clearance showed a tendency to increase, and tolvaptan
showed a consistent effect. Hypernatremia did not occur.
There was no exacerbation of the serum Cr level and no
adverse effect on renal function. We showed a decrease in
the serum Cr level in patients with stage 5 CKD. Tolvaptan
is an optional effective diuretic for patients with CKD.
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